Markers in urine and blood can reveal diabetes risk in patients with angina pectoris, according to the PhD thesis of Eirik Wilberg Rebnord.


  1. HbA1c does not predict prognosis in patients with angina pectoris.
  2. Kynurenine:tryptophan-ratio in urine is associated with increased risk of type 2 diabetes in angina patients.
  3. Patients with angina and high levels of serum carnitine metabolites have increased risk of type 2 diabetes.


Thesis: Biomarkers of metabolism and inflammation as predictors of coronary events and type 2 diabetes in patients with stable coronary artery disease – Prospective studies from the Western Norway Coronary angiography cohort
Candidate: Eirik Wilberg Rebnord
Time: November 2, 2018 at 11:15
Place: Haukeland University Hospital, Armauer Hansen House: Auditorium
Link to university website (in Norwegian)


(1) Glycated hemoglobin levels does not seem to influence the risk of an acute myocardial infarction or sudden cardiac death in patients with stable coronary artery disease. 2519 patients with suspected angina pectoris were included in the study between 2000 and 2004, and followed until 2006. There was no significant association between HbA1c and prognosis.

(2) A high kynurenine:tryptophan ratio measured in urine is linked to more than doubled risk of incident type 2 diabetes in patients with stable coronary artery disease. There was no association between kynurenine:tryptophan ratio in blood and risk of diabetes. The patients were followed for a median of 7.6 years.

(3/4) Patients with suspected angina pectoris and dysfunctional fatty acid metabolism have increased risk of type 2 diabetes. Higher levels of the carnitine metabolites trimethyllysine, butyrobetaine and palmitoylcarnitine independently predicted risk in patients followed for median 7.7 years.


(1) Rebnord, E. W., Pedersen, E. R., Strand, E., Svingen, G. F. T., Meyer, K., Schartum-Hansen, H., Løland, K. H., Seifert, R., Ueland, P. M., Nilsen, D. W. T., Nordrehaug, J. E., & Nygård, O. (2015). Glycated hemoglobin and long-term prognosis in patients with suspected stable angina pectoris without diabetes mellitus: a prospective cohort studyAtherosclerosis240(1), 115-120.

(2) Rebnord, E. W., Strand, E., Midttun, Ø., Svingen, G. F., Christensen, M. H., Ueland, P. M., Mellgren, G., Njølstad, P. R., Tell, G. S., Nygård, O. K. & Pedersen, E. R. (2017). The kynurenine: tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery diseaseDiabetologia60(9), 1712-1721.

(3) Strand, E., Rebnord, E. W., Flygel, M. R., Lysne, V., Svingen, G. F., Tell, G. S., Løland, K. H., Berge, R. K., Svardal, A., Nygård, O., & Pedersen, E. R. (2018). Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina PectorisThe Journal of Clinical Endocrinology & Metabolism103(3), 1033-1041.

(4) Rebnord, E. W., Strand, E., & Pedersen, E. R. (2018). Response to Letter to the Editor:“Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris”The Journal of Clinical Endocrinology & Metabolism103(11), 4039-4039.

Latest News

October 31, 2022

Pictures from Introductory Course to Cardiovascular Research and Medicine 2022

23 students completed NORHEART’s Introductory Course to Cardiovascular Research and Medicine in Oslo 17–21 October. As usual,…

Read more
October 04, 2022

Five abstract award winners at the Annual Symposium

The 20th Annual Norwegian Symposium on Heart Research was arranged by NORHEART and the Department…

Read more
April 30, 2022

Professor Eva Gerdts receives the 2022 Heart Research Award

The Norwegian Health Association has awarded the prestigious 2022 Heart Research Award (Hjerteforskningsprisen) to professor Eva…

Read more
April 09, 2022

A more relevant NORHEART for all heart researchers in Norway

NORHEART was established in 2013 as part of the research school program of the Research…

Read more
Norheart uses cookies for analytical purposes, content and ads customisation, and to further develop our services.
Learn more
Show again